Drug markets are defined not just by the number of patients, but by the medical practice of prescribing physicians. At the moment, platelet inhibitors targeting the GPIIb/IIIa platelet receptor are all the rage in cardiovascular medicine, but even the market for the three approved platelet inhibitor drugs is subject to changing attitudes about the management of patients with coronary syndromes.

In the U.S., many patients presenting with non-Q-wave myocardial infarction are treated with angioplasty to revascularize occluded arteries. However, results of the VANQWISH trial published in The New England Journal of Medicine suggest that those patients are managed as effectively without intervention.